AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Nuvectis Pharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG012BCR158
20.05▼ 0.84 (-4.02%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
20.89
Day's Range
19.83 – 20.86
52-Week Range
5.55 – 29.28
Volume
107.9K
Avg Volume
192.8K
Share Statistics
Shares Outstanding
Employees
13
Exchange
XNAS
Listed
2022-02-04
Share count as of July 31, 2026

Nuvectis Pharma, Inc. Common Stock (NVCT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Nuvectis Pharma, Inc. Common Stock (NVCT)
What is Nuvectis Pharma, Inc. Common Stock's Market Cap?
Nuvectis Pharma, Inc. Common Stock's Market Cap is $653.3M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvectis Pharma, Inc. Common Stock's Enterprise Value?
Nuvectis Pharma, Inc. Common Stock's Enterprise Value is $631.1M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvectis Pharma, Inc. Common Stock's Net Income (TTM)?
Nuvectis Pharma, Inc. Common Stock's Net Income (TTM) is -$27.8M, based on as-reported figures from SEC (XBRL) filings.
What is Nuvectis Pharma, Inc. Common Stock's Diluted EPS (TTM)?
Nuvectis Pharma, Inc. Common Stock's Diluted EPS (TTM) is -0.85, based on as-reported figures from SEC (XBRL) filings.
What is Nuvectis Pharma, Inc. Common Stock's Net Debt?
Nuvectis Pharma, Inc. Common Stock's Net Debt is -$22.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NVCTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
OPERATING EXPENSES
Research and development
General and administrative
OPERATING LOSS
Finance income
NET LOSS
TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
BASIC NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 (in dollars per share)
DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 (in dollars per share)